欧洲囊性纤维化患者的生存评估和社会经济因素的影响:回顾注册表队列研究摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 2002288 10.1183/13993003.02288 -2020 A1 McKone,爱德华·f188bet官网地址·A1 Ariti Cono A1杰克逊Abaigeal A1 Zolin,安娜A1卡尔,西沃恩·b·A1 Orenti Annalisa A1范任,内政大臣Jacqui A1 Lemonnier Lydie A1 Macek,米兰A1基奥,背景:欧洲囊性纤维化(CF)患者的中位生存期未知，可能受社会经济因素的影响。使用欧洲囊性纤维化协会患者登记处(ECFSPR)，获得了全欧洲CF患者的中位生存估计，并检查了社会经济地位对生存的影响。方法包括2010年至2014年在ECFSPR中已知在世的CF受试者。生存曲线采用Kaplan-Meier (KM)法估计。使用log rank检验评估生存曲线的差异。Cox回归分析用于评估社会经济因素与年龄特异性死亡风险之间的关系，并对性别、诊断年龄、CFTR基因型和移植状态进行调整。最终的分析包括了13个国家的31 987名受试者(135 833人年的随访)和1435例死亡。在ECFSPR中，这些患者的中位生存年龄为51.7岁(95% C.I. 50.0-53.4)。在调整了诊断时的年龄、性别、CFTR基因型和移植状态等潜在混杂因素后，仍然有强有力的证据表明社会经济因素和死亡率之间存在关联(p<0.001)。卫生保健支出较高的国家与卫生保健支出最低的国家相比，死亡率风险低46% (HR: 0.54, 95% CI: 0.45-0.64)。欧洲地区CF患者的中位生存期与其他地区报告的相比具有可比性，且因社会经济因素而有所不同。脚注:这篇手稿最近已被欧洲呼吸杂志接受发表。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. McKone reports grants and personal fees from Vertex Pharmaceutocals, personal fees from Novartis, non-financial support from A Menarini, grants from Gilead, outside the submitted work.Conflict of interest: Dr. Ariti has nothing to disclose.Conflict of interest: Dr. Jackson has nothing to disclose.Conflict of interest: Dr. Zolin has nothing to disclose.Conflict of interest: Dr. Carr reports non-financial support and other from Chiesi Pharmaceuticals, non-financial support and other from Vertex Pharmaceuticals, other from Zambon Pharmaceuticals, other from Insmed, outside the submitted work.Conflict of interest: Dr. Orenti has nothing to disclose.Conflict of interest: Dr. van Rens has nothing to disclose.Conflict of interest: Dr. LEMONNIER has nothing to disclose.Conflict of interest: Dr. Macek has nothing to disclose.Conflict of interest: Dr. Keogh has nothing to disclose.Conflict of interest: Dr. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals.